Background: The minimal or measurable residual disease (MRD) status post induction-consolidation is widely accepted as major surrogate endpoint that correlates with outcome in adult patients with newly diagnosed acute lymphoblastic leukemia (ALL). However, the optimal time-points of MRD assessment at complete remission (CR) or later during consolidation and its impact on outcome remain unclear.

Methods: We performed a retrospective chart review of 419 newly diagnosed adult patients with Philadelphia negative B-cell ALL who received treatment at the M.D. Anderson Cancer Center between 01/2000 and 01/2015 (Figure 1). Overall, 394 of 419 (94%) patients achieved CR. Two hundred and fifteen patients (51%) had available MRD assessment (by multicolor flow cytometry) at CR (1st time-point: median 24 days) and first post-CR MRD assessment (2nd time-point: median 3.6 months), and constitute the current studied cohort. MRD responses were stratified as MRD negative (undetectable), low-positive (≤0.1%), and high-positive (>0.1%).

Results: The median age for the study cohort (n=215) was 37 years (range 15-86), and 17% (n=37) had unfavorable cytogenetic profile, such as complex karyotype (n=9), KMT2A (MLL) rearrangement (n=14), and low hypodiploidy/near triploidy (n=14) (Table 1).

At first time-point (1TP), 148 patients (68%) were MRD negative and 67 (32%) were positive (Figure 2). Of the 148 patients with negative MRD at 1TP, 147 (99%) maintained it through second time-point (2TP). Fourteen of 16 (88%) patients with low-positive MRD and 33 of 51 (64%) with high-positive MRD at 1TP became MRD negative at 2TP. Patients who were MRD negative at both time-points, early MRD responders, had the 3-year event-free survival (EFS) and overall survival (OS) rates of 65% and 76%, respectively (Table 2). Patients with improved MRD status from positive to negative, late MRD responders, had lower 3-year EFS and OS rates, 42% and 58%, respectively (Figure 3, p<0.01). The 3-year EFS and OS rates were the lowest (16% and 49%, respectively) in patients with persistent MRD at both time points (p<0.01). Multivariate analysis showed that older age, KMT2A (MLL) rearrangement, and MRD positivity at 1TP only correlated with worse survival (Table 3).

Conclusion: The early achievement of MRD negative CR is a strong predictive for survival. Innovative combinations of conventional chemotherapy and targeted agents that induce early MRD eradication may have the potential to improve cure rates in adult ALL.

graphic
View largeDownload slide
Disclosures

Kantarjian:Daiichi-Sankyo: Research Funding; Astex: Research Funding; Actinium: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Research Funding; Cyclacel: Research Funding; Novartis: Research Funding; Ariad: Research Funding; Immunogen: Research Funding; Amgen: Honoraria, Research Funding; Agios: Honoraria, Research Funding; BMS: Research Funding; Takeda: Honoraria; Jazz Pharma: Research Funding; AbbVie: Honoraria, Research Funding. Khoury:Kiromic: Research Funding; Angle: Research Funding; Stemline Therapeutics: Research Funding. Ravandi:Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Xencor: Consultancy, Research Funding; Cyclacel LTD: Research Funding; Menarini Ricerche: Research Funding; Macrogenix: Consultancy, Research Funding; Selvita: Research Funding. Short:AstraZeneca: Consultancy; Takeda Oncology: Consultancy, Research Funding; Amgen: Honoraria. Loghavi:GLG Consultants: Consultancy; AlphaSights: Consultancy; MDACC: Employment. Cortes:BiolineRx: Consultancy; Novartis: Consultancy, Honoraria, Research Funding; Forma Therapeutics: Consultancy, Honoraria, Research Funding; Merus: Consultancy, Honoraria, Research Funding; Astellas Pharma: Consultancy, Honoraria, Research Funding; Jazz Pharmaceuticals: Consultancy, Research Funding; Daiichi Sankyo: Consultancy, Honoraria, Research Funding; Pfizer: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Research Funding; Sun Pharma: Research Funding; Immunogen: Consultancy, Honoraria, Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; Biopath Holdings: Consultancy, Honoraria. Garcia-Manero:Amphivena: Consultancy, Research Funding; Helsinn: Research Funding; Novartis: Research Funding; AbbVie: Research Funding; Celgene: Consultancy, Research Funding; Astex: Consultancy, Research Funding; Onconova: Research Funding; H3 Biomedicine: Research Funding; Merck: Research Funding. Kadia:Pfizer: Membership on an entity's Board of Directors or advisory committees, Research Funding; Jazz: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Research Funding; Bioline RX: Research Funding; BMS: Research Funding; Amgen: Membership on an entity's Board of Directors or advisory committees, Research Funding; Genentech: Membership on an entity's Board of Directors or advisory committees; Pharmacyclics: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Research Funding. Sasaki:Otsuka: Honoraria; Pfizer: Consultancy. Konopleva:Calithera: Research Funding; Stemline Therapeutics: Consultancy, Honoraria, Research Funding; Forty-Seven: Consultancy, Honoraria; Eli Lilly: Research Funding; AbbVie: Consultancy, Honoraria, Research Funding; Cellectis: Research Funding; Amgen: Consultancy, Honoraria; F. Hoffman La-Roche: Consultancy, Honoraria, Research Funding; Genentech: Honoraria, Research Funding; Ascentage: Research Funding; Kisoji: Consultancy, Honoraria; Reata Pharmaceuticals: Equity Ownership, Patents & Royalties; Ablynx: Research Funding; Astra Zeneca: Research Funding; Agios: Research Funding. Takahashi:Symbio Pharmaceuticals: Consultancy. Wierda:Gilead Sciences: Research Funding; Juno Therapeutics: Research Funding; KITE pharma: Research Funding; Sunesis: Research Funding; Miragen: Research Funding; Oncternal Therapeutics Inc.: Research Funding; Cyclcel: Research Funding; Acerta Pharma Inc: Research Funding; Pharmacyclics LLC: Research Funding; Genentech: Research Funding; AbbVie: Research Funding; GSK/Novartis: Research Funding; Loxo Oncology Inc.: Research Funding; Janssen: Research Funding; Xencor: Research Funding. Jain:Servier: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Cellectis: Research Funding; AstraZeneca: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Research Funding; ADC Therapeutics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Verastem: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen Pharmaceuticals, Inc.: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Genentech: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Adaptive Biotechnologies: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pharmacyclics, an AbbVie company: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Precision Biosciences: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Incyte: Research Funding. Verstovsek:Pragmatist: Consultancy; Incyte: Research Funding; Roche: Research Funding; NS Pharma: Research Funding; Celgene: Consultancy, Research Funding; Gilead: Research Funding; Promedior: Research Funding; CTI BioPharma Corp: Research Funding; Genetech: Research Funding; Blueprint Medicines Corp: Research Funding; Novartis: Consultancy, Research Funding; Sierra Oncology: Research Funding; Pharma Essentia: Research Funding; Astrazeneca: Research Funding; Ital Pharma: Research Funding; Protaganist Therapeutics: Research Funding; Constellation: Consultancy. Bose:Incyte Corporation: Consultancy, Research Funding, Speakers Bureau; Celgene Corporation: Consultancy, Research Funding; Blueprint Medicine Corporation: Consultancy, Research Funding; Kartos: Consultancy, Research Funding; Constellation: Research Funding; Pfizer: Research Funding; Astellas: Research Funding; NS Pharma: Research Funding; Promedior: Research Funding; CTI BioPharma: Research Funding. O'Brien:Sunesis: Consultancy, Research Funding; Pfizer: Consultancy, Honoraria, Research Funding; Regeneron: Research Funding; AbbVie: Consultancy, Honoraria; Acerta: Research Funding; Alexion: Consultancy; Gilead: Consultancy, Research Funding; Eisai: Consultancy; Pharmacyclics LLC, an AbbVie Company: Consultancy, Research Funding; Amgen: Consultancy; Kite: Research Funding; TG Therapeutics: Consultancy, Research Funding; Vaniam Group LLC: Consultancy; Verastem: Consultancy; Aptose Biosciences, Inc: Consultancy; GlaxoSmithKline: Consultancy; Janssen: Consultancy, Honoraria; Celgene: Consultancy; Astellas: Consultancy. Jabbour:Adaptive: Consultancy, Research Funding; Cyclacel LTD: Research Funding; BMS: Consultancy, Research Funding; Amgen: Consultancy, Research Funding; AbbVie: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Takeda: Consultancy, Research Funding.

Topics:
burkitt's lymphoma, leukemia, b-cell, acute, residual tumor, antigens, actinium, acute lymphocytic leukemia, b-cell acute lymphocytic leukemia, chemotherapy regimen, complete remission, flow cytometry

Author notes

*

Asterisk with author names denotes non-ASH members.

© 2019 by The American Society of Hematology
2019
Sign in via your Institution